Investing
AbbVie trims full-year profit forecast due to higher R&D expenses
© Reuters. Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) – AbbVie Inc (NYSE:) cut full-year profit forecast due to unfavorable impact from R&D and milestone expenses, the drugmaker said on Thursday.
The company now expects adjusted profit between $10.57 and $10.97 per share, compared with $10.72 to $11.12 per share it previously expected.
Read the full article here
-
Make Money7 days ago
How to Create and Sell Digital Products Online (Make Extra Money)
-
Investing7 days ago
Is Apple Releasing an ‘Ultra-Thin’ iPhone 17 Air? New Report
-
Investing6 days ago
Moldova breakaway region to face new power cuts on Saturday, officials say By Reuters
-
Investing7 days ago
US data center electricity and water use to increase significantly by 2028: report By Investing.com
-
Investing6 days ago
Reebok Co-Founder Backs Syntilay’s New AI, 3D-Printed Shoe
-
Side Hustles6 days ago
How to Survive High-Demand Seasons Without Losing Customers
-
Investing4 days ago
NFI Group surge after board reshaped with new appointments, chairperson By Investing.com
-
Passive Income7 days ago
How to Evolve From Manager to Mentor and Create a Lasting Impact